CBIO
Income statement / Annual
Last year (2025), Crescent Biopharma Inc.'s total revenue was $10.84 M,
and the percentage change from the previous year is not available.
In 2025, Crescent Biopharma Inc.'s net income was -$153.94 M.
See Crescent Biopharma Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$10.84 M |
$0.00 |
$10.00 K |
$75.00 K |
$1.16 M |
$10.16 M |
$0.00 |
$0.00 |
$0.00 |
$18.50 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$899.30 K
|
$275.12 K
|
$263.54 K
|
$0.00
|
| Gross Profit |
$10.84 M
|
$0.00
|
$10.00 K
|
$75.00 K
|
$1.16 M
|
$0.00
|
-$899.30 K
|
-$275.12 K
|
-$263.54 K
|
$0.00
|
| Gross Profit Ratio |
1
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$138.09 M
|
$28.06 M
|
$20.07 M
|
$28.39 M
|
$47.49 M
|
$44.93 M
|
$47.03 M
|
$40.09 M
|
$24.10 M
|
$23.28 M
|
| General & Administrative Expenses |
$25.39 M
|
$16.32 M
|
$19.21 M
|
$19.09 M
|
$17.12 M
|
$16.74 M
|
$14.36 M
|
$11.41 M
|
$9.83 M
|
$8.65 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$25.39 M
|
$16.32 M
|
$19.21 M
|
$19.09 M
|
$17.12 M
|
$16.74 M
|
$14.36 M
|
$11.41 M
|
$9.83 M
|
$8.65 M
|
| Other Expenses |
$0.00
|
$5.51 M
|
$637.00
|
$443.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$263.54 K
|
$0.00
|
| Operating Expenses |
$163.48 M
|
$49.90 M
|
$39.29 M
|
$47.48 M
|
$64.61 M
|
$61.67 M
|
$61.39 M
|
$51.51 M
|
$33.67 M
|
$31.93 M
|
| Cost And Expenses |
$163.48 M
|
$49.90 M
|
$39.29 M
|
$47.48 M
|
$64.61 M
|
$61.67 M
|
$61.39 M
|
$51.51 M
|
$33.93 M
|
$31.93 M
|
| Interest Income |
$2.88 M
|
$1.00 M
|
$2.38 M
|
$714.52 K
|
$19.77 K
|
$482.49 K
|
$3.50 M
|
$3.23 M
|
$651.21 K
|
$103.65 K
|
| Interest Expense |
$2.19 M
|
$852.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$84.00 K
|
$35.17 K
|
$153.30 K
|
$207.15 K
|
$264.60 K
|
$270.75 K
|
$899.30 K
|
$275.12 K
|
$263.54 K
|
$190.54 K
|
| EBITDA |
-$149.67 M |
-$44.17 M |
-$39.12 M |
-$47.20 M |
-$63.18 M |
-$51.24 M |
-$56.99 M |
-$51.23 M |
-$33.67 M |
-$31.72 M |
| EBITDA Ratio |
-13.8
|
0
|
-3912.14
|
-629.28
|
-54.48
|
-5.04
|
0
|
0
|
0
|
-1714.75
|
| Operating Income Ratio |
-14.08
|
0
|
-3927.53
|
-632.04
|
-54.71
|
-5.07
|
0
|
0
|
0
|
-1725.05
|
| Total Other Income/Expenses Net |
$690.00 K
|
$1.37 M
|
$2.38 M
|
$714.96 K
|
$19.77 K
|
$482.49 K
|
$3.50 M
|
$3.23 M
|
$651.21 K
|
$103.65 K
|
| Income Before Tax |
-$151.94 M
|
-$48.52 M
|
-$36.90 M
|
-$46.69 M
|
-$63.43 M
|
-$51.03 M
|
-$57.89 M
|
-$48.27 M
|
-$33.28 M
|
-$31.81 M
|
| Income Before Tax Ratio |
-14.01
|
0
|
-3689.88
|
-622.51
|
-54.69
|
-5.02
|
0
|
0
|
0
|
-1719.45
|
| Income Tax Expense |
$2.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$3.78 M
|
$3.23 M
|
$0.00
|
$0.00
|
| Net Income |
-$153.94 M
|
-$48.52 M
|
-$36.90 M
|
-$46.69 M
|
-$63.43 M
|
-$51.03 M
|
-$54.12 M
|
-$48.27 M
|
-$33.28 M
|
-$31.81 M
|
| Net Income Ratio |
-14.2
|
0
|
-3689.94
|
-622.52
|
-54.69
|
-5.02
|
0
|
0
|
0
|
-1719.45
|
| EPS |
-14.78 |
-1.4 |
-0.58 |
-0.89 |
-1.23 |
-1.12 |
-1.34 |
-1.18 |
-1.13 |
-1.5 |
| EPS Diluted |
-14.78 |
-1.4 |
-0.58 |
-0.89 |
-1.23 |
-1.12 |
-1.34 |
-1.18 |
-1.13 |
-1.5 |
| Weighted Average Shares Out |
$10.41 M
|
$19.50 M
|
$63.34 M
|
$52.53 M
|
$51.45 M
|
$45.72 M
|
$43.25 M
|
$41.04 M
|
$29.40 M
|
$21.26 M
|
| Weighted Average Shares Out Diluted |
$10.41 M
|
$19.50 M
|
$63.34 M
|
$52.53 M
|
$51.45 M
|
$45.72 M
|
$43.25 M
|
$41.04 M
|
$29.40 M
|
$21.26 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
